UA122962C2 - Спосіб лікування поширених солідних пухлин, які характеризуються наявністю мутантного алеля idh1 - Google Patents

Спосіб лікування поширених солідних пухлин, які характеризуються наявністю мутантного алеля idh1 Download PDF

Info

Publication number: UA122962C2
Authority: UA; Ukraine
Prior art keywords: compound; approximately; pharmaceutically acceptable; acceptable salt; solid dispersion
Prior art date: 2014-03-14

Application number

UAA201610408A

Other languages

English (en)

Ukrainian (uk)

Inventor

Чун-Хой Ґу

Чун-Хой ГУ

Original Assignee

Аджіос Фармасьютикалз, Інк.

Аджиос Фармасьютикалз, Инк

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-14

Filing date

2015-03-13

Publication date

2021-01-27

2015-03-13 Application filed by Аджіос Фармасьютикалз, Інк., Аджиос Фармасьютикалз, Инк filed Critical Аджіос Фармасьютикалз, Інк.

2021-01-27 Publication of UA122962C2 publication Critical patent/UA122962C2/uk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 130
150000001875 compounds Chemical class 0.000 title claims abstract description 74
238000000034 method Methods 0.000 claims abstract description 95
206010028980 Neoplasm Diseases 0.000 claims abstract description 55
229940125904 compound 1 Drugs 0.000 claims description 171
239000007962 solid dispersion Substances 0.000 claims description 138
150000003839 salts Chemical class 0.000 claims description 137
239000000203 mixture Substances 0.000 claims description 72
229920000642 polymer Polymers 0.000 claims description 69
238000011282 treatment Methods 0.000 claims description 53
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 51
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 51
238000004458 analytical method Methods 0.000 claims description 39
206010018338 Glioma Diseases 0.000 claims description 38
208000006990 cholangiocarcinoma Diseases 0.000 claims description 38
208000032612 Glial tumor Diseases 0.000 claims description 36
208000005243 Chondrosarcoma Diseases 0.000 claims description 29
108700028369 Alleles Proteins 0.000 claims description 28
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
206010009944 Colon cancer Diseases 0.000 claims description 27
206010060862 Prostate cancer Diseases 0.000 claims description 27
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 27
208000029742 colonic neoplasm Diseases 0.000 claims description 27
201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 27
201000001441 melanoma Diseases 0.000 claims description 27
230000035772 mutation Effects 0.000 claims description 26
210000004369 blood Anatomy 0.000 claims description 23
239000008280 blood Substances 0.000 claims description 23
239000000314 lubricant Substances 0.000 claims description 21
239000004094 surface-active agent Substances 0.000 claims description 21
239000000945 filler Substances 0.000 claims description 20
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
239000000126 substance Substances 0.000 claims description 19
229920002785 Croscarmellose sodium Polymers 0.000 claims description 16
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 16
229960001681 croscarmellose sodium Drugs 0.000 claims description 16
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 16
210000002700 urine Anatomy 0.000 claims description 16
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 15
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 15
229940075614 colloidal silicon dioxide Drugs 0.000 claims description 15
239000006185 dispersion Substances 0.000 claims description 15
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
239000008108 microcrystalline cellulose Substances 0.000 claims description 15
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 15
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
235000019359 magnesium stearate Nutrition 0.000 claims description 14
208000037844 advanced solid tumor Diseases 0.000 claims description 12
239000000080 wetting agent Substances 0.000 claims description 12
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 10
230000001419 dependent effect Effects 0.000 claims description 10
210000002381 plasma Anatomy 0.000 claims description 10
102000004190 Enzymes Human genes 0.000 claims description 9
108090000790 Enzymes Proteins 0.000 claims description 9
239000000463 material Substances 0.000 claims description 9
238000005259 measurement Methods 0.000 claims description 7
229930003427 Vitamin E Natural products 0.000 claims description 6
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
230000009467 reduction Effects 0.000 claims description 6
238000004611 spectroscopical analysis Methods 0.000 claims description 6
229940046009 vitamin E Drugs 0.000 claims description 6
239000011709 vitamin E Substances 0.000 claims description 6
235000019165 vitamin E Nutrition 0.000 claims description 6
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 5
238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 5
210000001124 body fluid Anatomy 0.000 claims description 4
239000010839 body fluid Substances 0.000 claims description 4
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
235000010855 food raising agent Nutrition 0.000 claims description 3
238000004949 mass spectrometry Methods 0.000 claims description 3
238000010922 spray-dried dispersion Methods 0.000 claims description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
239000002202 Polyethylene glycol Substances 0.000 claims description 2
238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 2
241000428352 Amma Species 0.000 claims 1
201000011510 cancer Diseases 0.000 abstract description 12
239000002904 solvent Substances 0.000 description 87
239000000523 sample Substances 0.000 description 47
239000000047 product Substances 0.000 description 43
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
238000001035 drying Methods 0.000 description 33
239000012071 phase Substances 0.000 description 30
238000011156 evaluation Methods 0.000 description 28
229910052799 carbon Inorganic materials 0.000 description 26
238000001694 spray drying Methods 0.000 description 26
238000011301 standard therapy Methods 0.000 description 24
239000007787 solid Substances 0.000 description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
239000003826 tablet Substances 0.000 description 20
239000000243 solution Substances 0.000 description 19
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
239000013078 crystal Substances 0.000 description 18
230000000694 effects Effects 0.000 description 18
239000007789 gas Substances 0.000 description 18
239000007921 spray Substances 0.000 description 18
HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 17
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
239000007884 disintegrant Substances 0.000 description 15
239000007788 liquid Substances 0.000 description 14
230000003285 pharmacodynamic effect Effects 0.000 description 14
230000008859 change Effects 0.000 description 13
201000010099 disease Diseases 0.000 description 13
239000003814 drug Substances 0.000 description 13
238000012216 screening Methods 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
238000001574 biopsy Methods 0.000 description 12
238000000113 differential scanning calorimetry Methods 0.000 description 12
239000003937 drug carrier Substances 0.000 description 12
231100000682 maximum tolerated dose Toxicity 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 12
238000002411 thermogravimetry Methods 0.000 description 12
229940079593 drug Drugs 0.000 description 11
239000012530 fluid Substances 0.000 description 11
239000000843 powder Substances 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 10
-1 crystalline forms Chemical class 0.000 description 10
239000002245 particle Substances 0.000 description 10
230000008569 process Effects 0.000 description 10
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
229910052757 nitrogen Inorganic materials 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
210000001185 bone marrow Anatomy 0.000 description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
229960003943 hypromellose Drugs 0.000 description 8
238000000634 powder X-ray diffraction Methods 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
206010061818 Disease progression Diseases 0.000 description 7
102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 7
108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 7
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 7
229960000583 acetic acid Drugs 0.000 description 7
239000001913 cellulose Substances 0.000 description 7
230000005750 disease progression Effects 0.000 description 7
239000012458 free base Substances 0.000 description 7
230000009477 glass transition Effects 0.000 description 7
239000006186 oral dosage form Substances 0.000 description 7
230000000306 recurrent effect Effects 0.000 description 7
230000004044 response Effects 0.000 description 7
239000012453 solvate Substances 0.000 description 7
231100000419 toxicity Toxicity 0.000 description 7
230000001988 toxicity Effects 0.000 description 7
230000007704 transition Effects 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000004698 Polyethylene Substances 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
238000002156 mixing Methods 0.000 description 6
230000003020 moisturizing effect Effects 0.000 description 6
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
238000005070 sampling Methods 0.000 description 6
238000005507 spraying Methods 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
238000001291 vacuum drying Methods 0.000 description 6
206010064571 Gene mutation Diseases 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000009826 distribution Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
231100000371 dose-limiting toxicity Toxicity 0.000 description 5
239000010419 fine particle Substances 0.000 description 5
238000005243 fluidization Methods 0.000 description 5
239000012362 glacial acetic acid Substances 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
108010021466 Mutant Proteins Proteins 0.000 description 4
102000008300 Mutant Proteins Human genes 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
229940109239 creatinine Drugs 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
239000008187 granular material Substances 0.000 description 4
230000006872 improvement Effects 0.000 description 4
239000012535 impurity Substances 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 4
229940057948 magnesium stearate Drugs 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
238000012545 processing Methods 0.000 description 4
239000013557 residual solvent Substances 0.000 description 4
238000012163 sequencing technique Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
238000002441 X-ray diffraction Methods 0.000 description 3
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 3
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
239000000090 biomarker Substances 0.000 description 3
238000010241 blood sampling Methods 0.000 description 3
230000005587 bubbling Effects 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
229940105329 carboxymethylcellulose Drugs 0.000 description 3
229940081734 cellulose acetate phthalate Drugs 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000001816 cooling Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000007907 direct compression Methods 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
238000010191 image analysis Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 3
229920001983 poloxamer Polymers 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
235000019814 powdered cellulose Nutrition 0.000 description 3
229920003124 powdered cellulose Polymers 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
229960001866 silicon dioxide Drugs 0.000 description 3
239000011877 solvent mixture Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
101000764357 Homo sapiens Protein Tob1 Proteins 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
102100026881 Protein Tob1 Human genes 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010041067 Small cell lung cancer Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229920006125 amorphous polymer Polymers 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
235000009120 camo Nutrition 0.000 description 2
244000213578 camo Species 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
230000001934 delay Effects 0.000 description 2
239000002274 desiccant Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
230000036541 health Effects 0.000 description 2
229920001903 high density polyethylene Polymers 0.000 description 2
239000004700 high-density polyethylene Substances 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000001050 lubricating effect Effects 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
229960002900 methylcellulose Drugs 0.000 description 2
RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
238000005895 oxidative decarboxylation reaction Methods 0.000 description 2
210000002824 peroxisome Anatomy 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229940106032 poloxamer 335 Drugs 0.000 description 2
229920001992 poloxamer 407 Polymers 0.000 description 2
229940044476 poloxamer 407 Drugs 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229940068965 polysorbates Drugs 0.000 description 2
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000009597 pregnancy test Methods 0.000 description 2
238000003825 pressing Methods 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
238000002390 rotary evaporation Methods 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
210000000582 semen Anatomy 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000002002 slurry Substances 0.000 description 2
229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
238000007711 solidification Methods 0.000 description 2
230000008023 solidification Effects 0.000 description 2
238000002336 sorption--desorption measurement Methods 0.000 description 2
241000894007 species Species 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
210000004243 sweat Anatomy 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229940033134 talc Drugs 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
210000001138 tear Anatomy 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000001757 thermogravimetry curve Methods 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
231100000402 unacceptable toxicity Toxicity 0.000 description 2
238000002562 urinalysis Methods 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
238000005303 weighing Methods 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
QRXBTPFMCTXCRD-UHFFFAOYSA-N 2-chloropyridine-4-carbonitrile Chemical compound ClC1=CC(C#N)=CC=N1 QRXBTPFMCTXCRD-UHFFFAOYSA-N 0.000 description 1
RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010050337 Cerumen impaction Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
101100301524 Drosophila melanogaster Reg-5 gene Proteins 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
208000009139 Gilbert Disease Diseases 0.000 description 1
208000022412 Gilbert syndrome Diseases 0.000 description 1
102000015779 HDL Lipoproteins Human genes 0.000 description 1
108010010234 HDL Lipoproteins Proteins 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000282553 Macaca Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
231100000605 Toxicity Class Toxicity 0.000 description 1
206010047289 Ventricular extrasystoles Diseases 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000012296 anti-solvent Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
238000004159 blood analysis Methods 0.000 description 1
238000004820 blood count Methods 0.000 description 1
238000007664 blowing Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000010410 calcium alginate Nutrition 0.000 description 1
239000000648 calcium alginate Substances 0.000 description 1
229960002681 calcium alginate Drugs 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
229960003340 calcium silicate Drugs 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
210000002939 cerumen Anatomy 0.000 description 1
210000003756 cervix mucus Anatomy 0.000 description 1
229940045110 chitosan Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
210000004913 chyme Anatomy 0.000 description 1
238000003181 co-melting Methods 0.000 description 1
238000001246 colloidal dispersion Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
229920001531 copovidone Polymers 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000002559 cytogenic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
238000007599 discharging Methods 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000002036 drum drying Methods 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000011985 exploratory data analysis Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000012527 feed solution Substances 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000000762 glandular Effects 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
231100001156 grade 3 toxicity Toxicity 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000000905 isomalt Substances 0.000 description 1
235000010439 isomalt Nutrition 0.000 description 1
HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
238000001646 magnetic resonance method Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000000282 nail Anatomy 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
231100000822 oral exposure Toxicity 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000000858 peroxisomal effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
210000004910 pleural fluid Anatomy 0.000 description 1
238000005498 polishing Methods 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920001290 polyvinyl ester Polymers 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000010926 purge Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
210000004915 pus Anatomy 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000002374 sebum Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000004513 sizing Methods 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
125000005591 trimellitate group Chemical group 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000012855 volatile organic compound Substances 0.000 description 1
210000004916 vomit Anatomy 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Ecology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

UAA201610408A 2014-03-14 2015-03-13 Спосіб лікування поширених солідних пухлин, які характеризуються наявністю мутантного алеля idh1 UA122962C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461953480P	2014-03-14	2014-03-14
PCT/US2015/020346 WO2015138837A1 (en)	2014-03-14	2015-03-13	Pharmaceutical compositions of therapeutically active compounds

Publications (1)

Publication Number	Publication Date
UA122962C2 true UA122962C2 (uk)	2021-01-27

Family

ID=54072439

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
UAA201610408A UA122962C2 (uk)	2014-03-14	2015-03-13	Спосіб лікування поширених солідних пухлин, які характеризуються наявністю мутантного алеля idh1
UAA202006348A UA129317C2 (uk)	2014-03-14	2015-03-13	Кристалічні форми (s)-n-((s)-1-(2-хлорфеніл)-2-((3,3-дифторциклобутил)аміно)-2-оксоетил)-1-(4-ціанопіридин-2-іл)-n-(5-фторпірдин-3-іл)-5-оксопіролідин-2-карбоксаміду

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
UAA202006348A UA129317C2 (uk)	2014-03-14	2015-03-13	Кристалічні форми (s)-n-((s)-1-(2-хлорфеніл)-2-((3,3-дифторциклобутил)аміно)-2-оксоетил)-1-(4-ціанопіридин-2-іл)-n-(5-фторпірдин-3-іл)-5-оксопіролідин-2-карбоксаміду

Country Status (28)

Country	Link
US (1)	US20170007661A1 (2)
EP (1)	EP3116491B1 (2)
JP (3)	JP6524119B2 (2)
KR (1)	KR102458157B1 (2)
CN (2)	CN112206232A (2)
AU (2)	AU2015229212B2 (2)
BR (2)	BR122023021436A2 (2)
CA (1)	CA2942070A1 (2)
CY (1)	CY1125205T1 (2)
DK (1)	DK3116491T3 (2)
EA (2)	EA034366B1 (2)
ES (1)	ES2881858T3 (2)
HR (1)	HRP20211233T1 (2)
HU (1)	HUE055209T2 (2)
IL (1)	IL247721B (2)
LT (1)	LT3116491T (2)
MA (1)	MA39725B1 (2)
MX (2)	MX2016011865A (2)
NZ (1)	NZ723860A (2)
PH (1)	PH12016501788B1 (2)
PL (1)	PL3116491T3 (2)
PT (1)	PT3116491T (2)
RS (1)	RS62178B1 (2)
SI (1)	SI3116491T1 (2)
SM (1)	SMT202100444T1 (2)
UA (2)	UA122962C2 (2)
WO (1)	WO2015138837A1 (2)
ZA (1)	ZA201606134B (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
WO2015010297A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
NZ723859A (en)	2014-03-14	2023-01-27	Servier Lab	Pharmaceutical compositions of therapeutically active compounds and their uses
FI3362065T3 (fi)	2015-10-15	2024-06-19	Servier Lab	Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
KR102699521B1 (ko)	2015-10-15	2024-08-26	르 라보레또레 쎄르비에르	악성 종양의 치료를 위한 조합물 요법
ES2905915T3 (es)	2015-12-04	2022-04-12	Servier Lab	Procedimientos de tratamiento de neoplasias malignas
US11241455B2 (en)	2016-01-15	2022-02-08	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Methods of treating disease by metabolic control of T-cell differentiation
MA43640A (fr) *	2016-02-26	2018-11-28	Agios Pharmaceuticals Inc	Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
US11179360B2 (en)	2016-11-02	2021-11-23	University Of Cincinnati	Compositions and methods for treating patients suffering from glioma or leukemia
US20190381025A1 (en) *	2017-01-20	2019-12-19	Constellation Pharmaceuticals, Inc.	Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
KR102707847B1 (ko) *	2017-09-22	2024-09-23	치아타이 티안큉 파마수티컬 그룹 주식회사	결정형 설파마이드 화합물
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
EA202190217A1 (ru) *	2018-07-06	2021-04-16	Аджиос Фармасьютикалз, Инк.	Формы ивосидениба и фармацевтические композиции
US20210069113A1 (en) *	2019-09-11	2021-03-11	Modavar Pharmaceuticals LLC	Solid unit dosage form for dose individualized drug delivery
AR123228A1 (es)	2020-08-12	2022-11-09	Servier Pharmaceuticals Llc	Formas en estado sólido de un compuesto orgánico
ES2972441T3 (es) *	2020-10-02	2024-06-12	Lonza Bend Inc	Acido acético como auxiliar de procesamiento en el secado por pulverización para fármacos básicos
CN112022812B (zh) *	2020-11-03	2021-01-29	上海亚盛医药科技有限公司	一种包含杂环类化合物的组合物、其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8343548B2 (en) *	2006-08-08	2013-01-01	Shin-Etsu Chemical Co., Ltd.	Solid dosage form comprising solid dispersion
MX2009006806A (es) *	2006-12-22	2009-08-27	Vertex Pharma	Secado por rocio fluidizado.
JP2012509321A (ja) *	2008-11-21	2012-04-19	ミレニアムファーマシューティカルズ，インコーポレイテッド	癌および他の疾患または障害の処置のための、４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの乳酸塩およびその薬学的組成物
US20120121515A1 (en) *	2009-03-13	2012-05-17	Lenny Dang	Methods and compositions for cell-proliferation-related disorders
WO2010144338A1 (en) *	2009-06-08	2010-12-16	Abraxis Bioscience, Llc	Triazine derivatives and their therapeutical applications
US8652534B2 (en) *	2009-10-14	2014-02-18	Berry Pharmaceuticals, LLC	Compositions and methods for treatment of mammalian skin
KR20190120458A (ko) *	2010-10-21	2019-10-23	메디베이션 테크놀로지즈 엘엘씨	결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
CN102827170A (zh) *	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
PE20142098A1 (es) *	2012-01-06	2015-01-08	Agios Pharmaceuticals Inc	Compuestos terapeuticamente activos y sus metodos de uso
US9474779B2 (en) *	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
WO2014015422A1 (en) *	2012-07-27	2014-01-30	Ontario Institute For Cancer Research	Cellulose-based nanoparticles for drug delivery
WO2015127173A1 (en) *	2014-02-20	2015-08-27	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use

2015
- 2015-03-13 MA MA39725A patent/MA39725B1/fr unknown
- 2015-03-13 NZ NZ723860A patent/NZ723860A/en unknown
- 2015-03-13 CA CA2942070A patent/CA2942070A1/en active Pending
- 2015-03-13 DK DK15761216.9T patent/DK3116491T3/da active
- 2015-03-13 SI SI201531665T patent/SI3116491T1/sl unknown
- 2015-03-13 UA UAA201610408A patent/UA122962C2/uk unknown
- 2015-03-13 WO PCT/US2015/020346 patent/WO2015138837A1/en not_active Ceased
- 2015-03-13 US US15/125,884 patent/US20170007661A1/en not_active Abandoned
- 2015-03-13 PL PL15761216T patent/PL3116491T3/pl unknown
- 2015-03-13 RS RS20210962A patent/RS62178B1/sr unknown
- 2015-03-13 EA EA201691844A patent/EA034366B1/ru unknown
- 2015-03-13 JP JP2016575626A patent/JP6524119B2/ja active Active
- 2015-03-13 CN CN202010472904.XA patent/CN112206232A/zh active Pending
- 2015-03-13 PT PT157612169T patent/PT3116491T/pt unknown
- 2015-03-13 AU AU2015229212A patent/AU2015229212B2/en active Active
- 2015-03-13 SM SM20210444T patent/SMT202100444T1/it unknown
- 2015-03-13 BR BR122023021436-6A patent/BR122023021436A2/pt not_active Application Discontinuation
- 2015-03-13 BR BR112016021012-3A patent/BR112016021012B1/pt active IP Right Grant
- 2015-03-13 ES ES15761216T patent/ES2881858T3/es active Active
- 2015-03-13 EP EP15761216.9A patent/EP3116491B1/en active Active
- 2015-03-13 HU HUE15761216A patent/HUE055209T2/hu unknown
- 2015-03-13 MX MX2016011865A patent/MX2016011865A/es unknown
- 2015-03-13 HR HRP20211233TT patent/HRP20211233T1/hr unknown
- 2015-03-13 LT LTEP15761216.9T patent/LT3116491T/lt unknown
- 2015-03-13 KR KR1020167027887A patent/KR102458157B1/ko active Active
- 2015-03-13 UA UAA202006348A patent/UA129317C2/uk unknown
- 2015-03-13 EA EA202090098A patent/EA202090098A1/ru unknown
- 2015-03-13 CN CN201580019581.6A patent/CN106163507B/zh active Active
2016
- 2016-09-05 ZA ZA2016/06134A patent/ZA201606134B/en unknown
- 2016-09-08 IL IL247721A patent/IL247721B/en active IP Right Grant
- 2016-09-13 MX MX2021001739A patent/MX2021001739A/es unknown
- 2016-09-13 PH PH12016501788A patent/PH12016501788B1/en unknown
2019
- 2019-04-26 JP JP2019085619A patent/JP2019163278A/ja not_active Withdrawn
- 2019-09-18 AU AU2019232825A patent/AU2019232825B2/en active Active
2021
- 2021-03-05 JP JP2021035053A patent/JP2021088605A/ja not_active Withdrawn
- 2021-08-02 CY CY20211100687T patent/CY1125205T1/el unknown

Also Published As

Publication number	Publication date
LT3116491T (lt)	2021-08-10
CN112206232A (zh)	2021-01-12
JP2019163278A (ja)	2019-09-26
IL247721A0 (en)	2016-11-30
EA202090098A1 (ru)	2020-11-30
JP2021088605A (ja)	2021-06-10
US20170007661A1 (en)	2017-01-12
MX2021001739A (es)	2021-04-19
EA034366B1 (ru)	2020-01-31
PH12016501788A1 (en)	2016-12-19
DK3116491T3 (da)	2021-08-09
BR122023021440A2 (pt)	2023-12-12
AU2019232825A1 (en)	2019-10-10
EP3116491A4 (en)	2017-11-15
AU2019232825B2 (en)	2021-08-05
UA129317C2 (uk)	2025-03-19
EP3116491A1 (en)	2017-01-18
CY1125205T1 (el)	2023-03-24
CA2942070A1 (en)	2015-09-17
RS62178B1 (sr)	2021-08-31
HRP20211233T1 (hr)	2021-10-29
BR122023021436A2 (pt)	2023-12-12
SI3116491T1 (sl)	2021-12-31
KR20160124907A (ko)	2016-10-28
CN106163507B (zh)	2020-06-26
JP2017508804A (ja)	2017-03-30
PT3116491T (pt)	2021-08-10
BR112016021012A2 (pt)	2018-08-07
IL247721B (en)	2020-04-30
JP6524119B2 (ja)	2019-06-05
MA39725B1 (fr)	2021-09-30
ES2881858T3 (es)	2021-11-30
SMT202100444T1 (it)	2021-09-14
EA201691844A1 (ru)	2016-12-30
BR112016021012B1 (pt)	2024-01-23
WO2015138837A1 (en)	2015-09-17
ZA201606134B (en)	2024-01-31
AU2015229212A1 (en)	2016-09-22
MX2016011865A (es)	2017-04-13
NZ723860A (en)	2023-04-28
AU2015229212B2 (en)	2019-06-20
PH12016501788B1 (en)	2021-12-15
PL3116491T3 (pl)	2022-02-07
EP3116491B1 (en)	2021-05-05
CN106163507A (zh)	2016-11-23
KR102458157B1 (ko)	2022-10-24
HUE055209T2 (hu)	2021-11-29

Publication	Publication Date	Title
JP7801865B2 (ja)	2026-01-19	治療活性化合物の医薬組成物
UA122962C2 (uk)	2021-01-27	Спосіб лікування поширених солідних пухлин, які характеризуються наявністю мутантного алеля idh1
HK40044696A (en)	2021-10-08	Pharmaceutical compositions of therapeutically active compounds and uses thereof
EA051161B1 (ru)	2025-10-09	Фармацевтические композиции терапевтически активных соединений
HK40043528A (en)	2021-09-17	Pharmaceutical compositions of therapeutically active compounds
BR122023021440B1 (pt)	2024-10-15	Composições farmacêuticas para tratar câncer
HK1233185B (en)	2022-02-11	Pharmaceutical compositions of therapeutically active compounds
BR112016021232B1 (pt)	2023-09-19	Composição farmacêutica para administração oral compreendendo (s)-n-((s)-1-(2-clorofenil)-2-((3,3-difluorociclobutil)amino )-2-oxoetil)-1-(4- cianopiridin-2-il)-n-(5-fluoropiridin-3-il)-5- oxopirrolidina-2-carboxamida e uso da referida composição